Skip to main content

Russia’s Sputnik V vaccine looks good in early analysis

posted onFebruary 4, 2021
by l33tdawg
Arstechnica
Credit: Arstechnica

Yesterday, the people behind Russia's leading vaccine, termed Sputnik V, issued a preliminary analysis of its function. The news was quite good: while the trial is ongoing and final results will have to wait, the interim data suggests that the vaccine could be over 90 percent effective.

Sputnik V is based on similar technology to the vaccines being developed by Johnson & Johnson and the Oxford/AstraZeneca collaboration. Strikingly, however, the preliminary efficiency is quite a bit higher than those vaccines are showing, and it's not clear how the Sputnik-specific features could account for the difference.

The results come out of a Phase III clinical trial involving roughly 21,000 participants being run in Moscow. Participants were all over the age of 18, hadn't received other vaccinations recently, weren't pregnant or drug users, and met a number of other criteria. PCR-based SARS-CoV-2 tests were performed at enrollment, and participants were also tested for the presence of antibodies against the virus.

Source

Tags

Industry News

You May Also Like

Recent News

Tuesday, November 19th

Friday, November 8th

Friday, November 1st

Tuesday, July 9th

Wednesday, July 3rd

Friday, June 28th

Thursday, June 27th

Thursday, June 13th

Wednesday, June 12th

Tuesday, June 11th